For the quarter ending 2025-09-30, CLDWW had $5,215K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Amortization of debt discount and financing costs | 0 | 0 |
| Net loss | -5,181 | -10,823 |
| Depreciation and amortization expense | 427 | 801 |
| Stock-based compensation | 529 | 1,129 |
| Change in fair value of other liabilities and derivatives | 100 | -16 |
| Prepaid expenses and other current assets | -118 | 156 |
| Accounts payable | -191 | -733 |
| Accrued expenses and other current liabilities | 264 | -1,449 |
| Operating lease right of use liability | -304 | -764 |
| Net cash used in operating activities | -4,238 | -12,011 |
| Purchases of machinery and equipment | 27 | 64 |
| Net cash used in investing activities | -27 | -64 |
| Proceeds from exercise of common stock warrants | 0 | 0 |
| Proceeds from issuance of noncontrolling interest in nova cell | 0 | - |
| Related party proceeds from issuance of loan payable | 0 | 0 |
| Proceeds from issuance of convertible notes payable | 0 | 0 |
| Proceeds from issuance of common shares and warrants per subscription agreement | 0 | - |
| Proceeds from issuance of promissory note | 0 | - |
| Repayment of convertible note payable | 0 | 0 |
| Payment of debt issuance costs | 0 | 0 |
| Proceeds from public offerings | 6,090 | 6,573 |
| Proceeds from warrant inducement financing | 4,136 | 0 |
| Proceeds from registered direct offering | 0 | 3,503 |
| Proceeds from exercise of pre-funded warrants | 2 | 3 |
| Repayment of financing lease obligations | 29 | 34 |
| Repayment of principal on term notes payable | 0 | 200 |
| Repayment of principal on related party bridge loan payable | 0 | 200 |
| Payment of financing costs | 344 | 381 |
| Repayment of principal on related party term notes payable | 375 | 1,625 |
| Net cash provided by financing activities | 9,480 | 7,639 |
| Effect of exchange rate changes on cash | 0 | 6 |
| Net increase (decrease) in cash and restricted cash | 5,215 | -4,430 |
| Cash and cash equivalents at beginning of period | 9,809 | - |
| Cash and cash equivalents at end of period | 10,594 | - |
Calidi Biotherapeutics, Inc. (CLDWW)
Calidi Biotherapeutics, Inc. (CLDWW)